So, it appears the Australian medical cannabis industry players listed on the ASX need to get some money in the coffers.

They are hamstrung by TGA and govt rules and regs until trials finish sometime in the 23rd or 24th century for approved product.

THE FIRST GENERATION OF AUSTRALIAN FULL SPECTRUM CBD USERS

So the solution is to feed the general public lolly versions…

See our story

Emyria and Cann Group ink deal to sell CBD placebo in Australia

 

Here’s the Althea announcement on their  2omg  dose product which of course are innovative and  flexi for price-sensitive patients.

The most important thing to notice about this press release is the final bit which says

 

Althea expects that the new ‘flexi’ 20ml product range will increase patient numbers and create incremental sales for the business

For full ASX announcement – read here

 

 

ALTHEA LAUNCHES INNOVATIVE RANGE OF 20ML ‘FLEXI’ PRODUCTS

Investment Highlights:

  • Althea has launched a new and innovative range of ‘flexi’ 20ml cannabis oil products
  • The smaller 20ml unit size provides new medicinal cannabis patients with an option to trial the medication over the recommended 2 or 3-week titration period
  • The expanded Althea product portfolio also provides price-sensitive patients with a lower entry point
  • Althea expects that the new ‘flexi’ 20ml product range will increase patient numbers and create incremental sales for the business

For full ASX announcement – read here

02358112